^
    4d
    REALiTEC: A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (clinicaltrials.gov)
    P=N/A, N=180, Recruiting, Janssen-Cilag Ltd. | Trial completion date: Jul 2024 --> Jan 2026
    Trial completion date
    |
    Tecvayli (teclistamab-cqyv)
    4d
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jun 2027 --> Apr 2026
    Trial primary completion date • Combination therapy
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    4d
    Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1. (PubMed, Blood)
    These findings illustrate the importance of the contribution of the immune landscape to T-cell redirection therapy response. This trial was registered at www.ClinicalTrials.gov, NCT03145181/NCT04557098.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    Tecvayli (teclistamab-cqyv)
    6d
    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion (clinicaltrials.gov)
    P1/2, N=76, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    ABBV-383 IV
    10d
    IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Dickran Kazandjian, MD
    New P2 trial • Combination therapy • Minimal residual disease
    |
    linvoseltamab (REGN5458)
    10d
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=130, Not yet recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P1 trial • Trispecific
    12d
    Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Regeneron Pharmaceuticals
    New P1 trial
    |
    Dupixent (dupilumab) • linvoseltamab (REGN5458)
    14d
    Elranatamab in R/R Multiple Myeloma (clinicaltrials.gov)
    P2, N=32, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm) • Abecma (idecabtagene vicleucel)
    17d
    MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (clinicaltrials.gov)
    P2, N=120, Recruiting, Pfizer | N=92 --> 120
    Enrollment change • Combination therapy
    |
    lenalidomide • Elrexfio (elranatamab-bcmm) • Ogsiveo (nirogacestat)
    21d
    Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Case Comprehensive Cancer Center
    New P2 trial
    |
    Tecvayli (teclistamab-cqyv) • Sylvant (siltuximab)
    28d
    BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Luminary Therapeutics
    New P1 trial • CAR T-Cell Therapy
    1m
    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, AbbVie | Phase classification: P1 --> P1/2
    Phase classification • Adverse events
    |
    ABBV-383 IV
    1m
    MajesTEC-7: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=1590, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: May 2029 --> Apr 2031
    Trial primary completion date • Combination therapy
    |
    lenalidomide • Darzalex Faspro (daratumumab/hyaluronidase) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Pfizer | N=14 --> 90
    Enrollment change • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    1m
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=270, Recruiting, TeneoOne Inc. | Trial completion date: Nov 2028 --> Jul 2031
    Trial completion date • Adverse events • Combination therapy
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • ABBV-383 IV
    1m
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=156, Recruiting, Celgene | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Feb 2032
    Enrollment open • Trial primary completion date • Combination therapy
    |
    alnuctamab (CC-93269) • mezigdomide (CC-92480)
    1m
    LMY-920-002: LMY-920 for Treatment of Relapsed or Refractory Myeloma (clinicaltrials.gov)
    P1, N=30, Recruiting, Luminary Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    1m
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov)
    P1/2, N=154, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MBS314
    2ms
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov)
    P1/2, N=154, Not yet recruiting, Beijing Mabworks Biotech Co., Ltd. | Initiation date: Jan 2024 --> Apr 2024
    Trial initiation date
    |
    MBS314
    2ms
    Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
    P2, N=50, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Nov 2023
    Enrollment open • Trial initiation date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb (clinicaltrials.gov)
    P2, N=187, Active, not recruiting, Pfizer | Trial completion date: Apr 2024 --> Dec 2025
    Trial completion date • Immunomodulating
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    LINKER-AL2: A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (clinicaltrials.gov)
    P1/2, N=220, Not yet recruiting, Regeneron Pharmaceuticals
    New P1/2 trial
    |
    linvoseltamab (REGN5458)
    2ms
    A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (clinicaltrials.gov)
    P1, N=100, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Jun 2028 --> Mar 2028 | Trial primary completion date: Aug 2026 --> Apr 2027
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    Elrexfio (elranatamab-bcmm) • iberdomide (CC-220)
    2ms
    MajesTEC-3: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=587, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2026 --> Dec 2028
    Trial completion date • Combination therapy
    |
    bortezomib • pomalidomide • Darzalex Faspro (daratumumab/hyaluronidase) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    2ms
    MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=282, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2026 --> Jul 2026
    Trial completion date
    |
    Tecvayli (teclistamab-cqyv)
    2ms
    REALiTEC: A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (clinicaltrials.gov)
    P=N/A, N=180, Recruiting, Janssen-Cilag Ltd.
    New trial
    |
    Tecvayli (teclistamab-cqyv)
    2ms
    Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, PETHEMA Foundation
    New P2 trial
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    MagnetisMM-1: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=101, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Immunomodulating • Metastases
    |
    lenalidomide • pomalidomide • Elrexfio (elranatamab-bcmm)
    2ms
    Descartes-25 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Cartesian Therapeutics | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date
    2ms
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jun 2024 --> Oct 2024
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)
    2ms
    ERICA: Self-administration of Subcutaneous Elranatamab in the Patients' Homes. (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Odense University Hospital | Initiation date: Jan 2024 --> May 2024
    Trial initiation date
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    Plan Development for Giving Teclistamab in the Outpatient Setting (clinicaltrials.gov)
    P4, N=15, Not yet recruiting, University Health Network, Toronto
    New P4 trial
    |
    Actemra IV (tocilizumab) • Tecvayli (teclistamab-cqyv)
    2ms
    ALUMMINATE: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=466, Not yet recruiting, Celgene
    New P3 trial
    |
    carfilzomib • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab/hyaluronidase) • alnuctamab (CC-93269)
    2ms
    Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (clinicaltrials.gov)
    P3, N=492, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • carfilzomib • pomalidomide • Elrexfio (elranatamab-bcmm) • Empliciti (elotuzumab)
    3ms
    LINKER-SMM1: A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    linvoseltamab (REGN5458)
    3ms
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    3ms
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov)
    P1/2, N=154, Not yet recruiting, Beijing Mabworks Biotech Co., Ltd.
    New P1/2 trial
    |
    MBS314
    3ms
    A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) (clinicaltrials.gov)
    P1/2, N=101, Recruiting, Sanofi | Trial completion date: Mar 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    IPH6401
    3ms
    Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=55, Not yet recruiting, AbbVie
    New P1 trial • Adverse events
    |
    ABBV-383 IV
    3ms
    A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Pfizer
    New P1 trial • Combination therapy
    |
    Elrexfio (elranatamab-bcmm) • iberdomide (CC-220)
    3ms
    Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial • Pre-transplantation • Post-transplantation
    |
    lenalidomide • Elrexfio (elranatamab-bcmm) • busulfan • captisol-enabled melphalan • plerixafor